Patents by Inventor Matthew Scanlan

Matthew Scanlan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for inducing cell lysis with immunogenic portions of NY-ESO-1 protein
    Patent number: 8541202
    Abstract: The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: September 24, 2013
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Alexander Knuth, Elke Jäger, Yao-tseng Chen, Matthew Scanlan, Ali Gure, Gerd Ritter, Lloyd J. Old, Jan W. Drijfhout
  • METHOD FOR INDUCING CELL LYSIS WITH IMMUNOGENIC PORTIONS OF NY-ESO-1 PROTEIN
    Publication number: 20120231035
    Abstract: The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.
    Type: Application
    Filed: February 24, 2012
    Publication date: September 13, 2012
    Inventors: Alexander Knuth, Elke Jäger, Yao-tseng Chen, Matthew Scanlan, Ali Gure, Gerd Ritter, Lloyd J. Old, Jan W. Drijfhout
  • Method for inducing cell lysis with immunogenic portions of NY-ESO-1 protein
    Patent number: 8142786
    Abstract: The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.
    Type: Grant
    Filed: January 10, 2011
    Date of Patent: March 27, 2012
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Alexander Knuth, Elke Jäger, Yao-tseng Chen, Matthew Scanlan, Ali Gure, Gerd Ritter, Lloyd J. Old, Jan W. Drijfhout
  • A34 AND A33-LIKE 3 DNA PROTEIN, ANTIBODIES THERETO AND METHODS OF TREATMENT USING SAME
    Publication number: 20120039892
    Abstract: Polynucleotide molecules and polypeptide molecules A34 and A33-like 3 are described, as well as antibodies to polypeptide molecules A34 and A33-like 3. Also described are methods of detecting cancers expressing these polypeptides, and methods and kits for diagnosing said cancers, and methods of inhibiting effects of a cancer in a patient.
    Type: Application
    Filed: September 15, 2011
    Publication date: February 16, 2012
    Applicant: Ludwig Institute for Cancer Research
    Inventors: Matthew Scanlan, Cynthia H. Scanlan, Gerd Ritter, Lloyd Old, Achim Jungbluth
  • Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
    Patent number: 8071717
    Abstract: The invention relates to newly identified cancer associated antigens. It has been discovered that each of these molecules provokes antibodies when expressed by a subject. The ramifications of this observation are also a part of this invention.
    Type: Grant
    Filed: October 27, 2009
    Date of Patent: December 6, 2011
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Dirk Jager, Elisabeth Stockert, Matthew Scanlan, Alexander Knuth, Lloyd Old, Ali Gure, Yao-Tseng Chen, Elke Jager
  • Method for inducing cell lysis with immunogenic portions of NY-ESO-1 protein
    Publication number: 20110182944
    Abstract: The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.
    Type: Application
    Filed: January 10, 2011
    Publication date: July 28, 2011
    Inventors: Alexander Knuth, Elke Jäger, Yao-tseng Chen, Matthew Scanlan, Ali Gure, Gerd Ritter, Lloyd J. Old, Jan W. Drijfhout
  • Isolated nucleic acid molecules which encode immunogenic portions of NY-ESO-1 protein
    Patent number: 7888100
    Abstract: The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.
    Type: Grant
    Filed: August 4, 2006
    Date of Patent: February 15, 2011
    Assignees: Memorial Sloan-Kettering Cancer Research, Ludwig Institute for Cancer Research, Cornell Research Foundation, Inc.
    Inventors: Alexander Knuth, Elke Jäger, Yao-tseng Chen, Matthew Scanlan, Ali Gure, Gerd Ritter, Lloyd J. Old, Jan W. Drijfhout
  • Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
    Publication number: 20100278850
    Abstract: The invention relates to newly identified cancer associated antigens. It has been discovered that each of these molecules provokes antibodies when expressed by a subject. The ramifications of this observation are also a part of this invention.
    Type: Application
    Filed: October 27, 2009
    Publication date: November 4, 2010
    Inventors: Dirk Jager, Elisabeth Stockert, Matthew Scanlan, Alexander Knuth, Lloyd Old, Ali Gure, Yao-Tseng Chen, Elke Jager
  • Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per SE, and uses thereof
    Patent number: 7795409
    Abstract: The invention relates to newly identified cancer associated antigens. It has been discovered that each of these molecules provokes antibodies when expressed by a subject. The ramifications of this observation are also a part of this invention.
    Type: Grant
    Filed: January 30, 2008
    Date of Patent: September 14, 2010
    Assignees: Ludwig Institute for Cancer Research, Cornell Research Foundation, Inc.
    Inventors: Dirk Jager, Elisabeth Stockert, Barry C. Picker, legal representative, Matthew Scanlan, Cynthia H. Scanlan, legal representative, Ali Gure, Elke Jager, Alexander Knuth, Lloyd Old, Yao-Tseng Chen
  • Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
    Patent number: 7622568
    Abstract: The invention relates to newly identified cancer associated antigens. It has been discovered that each of these molecules provokes antibodies when expressed by a subject. The ramifications of this observation are also a part of this invention.
    Type: Grant
    Filed: November 12, 2007
    Date of Patent: November 24, 2009
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Dirk Jager, Elisabeth Stockert, Matthew Scanlan, Alexander Knuth, Lloyd Old, Ali Gure, Yao-Tseng Chen, Elke Jager
  • A34 AND A33-LIKE 3 DNA PROTEIN, ANTIBODIES THERETO AND METHODS OF TREATMENT USING SAME
    Publication number: 20090263394
    Abstract: Polynucleotide molecules and polypeptide molecules A34 and A33-like 3 are described, as well as antibodies to polypeptide molecules A34 and A33-like 3. Also described are methods of detecting cancers expressing these polypeptides, and methods and kits for diagnosing said cancers, and methods of inhibiting effects of a cancer in a patient.
    Type: Application
    Filed: February 17, 2009
    Publication date: October 22, 2009
    Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH
    Inventors: Matthew Scanlan, Cynthia Scanlan, Gerd Ritter, Lioyd Old, Achim Jungbluth
  • Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per SE, and uses thereof
    Publication number: 20090203123
    Abstract: The invention relates to newly identified cancer associated antigens. It has been discovered that each of these molecules provokes antibodies when expressed by a subject. The ramifications of this observation are also a part of this invention.
    Type: Application
    Filed: January 30, 2008
    Publication date: August 13, 2009
    Inventors: Dirk Jager, Elisabeth Stockert, Matthew Scanlan, Ali Gure, Elke Jager, Alexander Knuth, Lloyd Old, Yao-Tseng Chen, Barry C. Picker, Cynthia H. Scanlan
  • A34 and A33-like 3 DNA, proteins, antibodies thereto and methods of treatment using same
    Patent number: 7521543
    Abstract: Polynucleotide molecules and polypeptide molecules A34 and A33-like 3 are described, as well as antibodies to polypeptide molecules A34 and A33like 3. Also described are methods of detecting cancers expressing these polypeptides, and methods and kits for diagnosing said cancers, and methods of inhibiting effects of a cancer in a patient.
    Type: Grant
    Filed: October 23, 2003
    Date of Patent: April 21, 2009
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Cynthia Scanlan, legal representative, Gerd Ritter, Lloyd Old, Achim Jungbluth, Matthew Scanlan
  • Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
    Publication number: 20080177031
    Abstract: The invention relates to newly identified cancer associated antigens. It has been discovered that each of these molecules provokes antibodies when expressed by a subject. The ramifications of this observation are also a part of this invention.
    Type: Application
    Filed: November 12, 2007
    Publication date: July 24, 2008
    Inventors: Dirk Jager, Elisabeth Stockert, Matthew Scanlan, Alexander Knuth, Lloyd Old, Ali Gure, Yao-Tseng Chen, Elke Jager
  • Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
    Patent number: 7354992
    Abstract: The invention relates to newly identified cancer associated antigens. It has been discovered that each of these molecules provokes antibodies when expressed by a subject. The ramifications of this observation are also a part of this invention.
    Type: Grant
    Filed: December 4, 2003
    Date of Patent: April 8, 2008
    Assignees: Ludwig Institute For Cancer Research, Cornell Research Foundation, Inc.
    Inventors: Dirk Jager, Barry C. Picker, legal representative, Cynthia H. Scanlan, legal representative, Ali Gure, Elke Jager, Alexander Knuth, Lloyd Old, Yao-Tseng Chen, Elisabeth Stockert, Matthew Scanlan
  • Isolated nucleic acid molecules encoding ESO-1 peptides and uses thereof
    Patent number: 7291335
    Abstract: The invention relates to antibodies which bind to the cancer associated antigen NY-ESO-1. Both polyclonal and monoclonal antibodies are part of the invention, as are chimeric forms of the antibodies, and binding portions of antibodies. Uses of these antibodies are described. Also described are truncated, recombinant forms of the cancer associated antigen.
    Type: Grant
    Filed: December 17, 2001
    Date of Patent: November 6, 2007
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Elisabeth Stockert, Elke Jäger, Yao-tseng Chen, Matthew Scanlan, Alexander Knuth, Lloyd J. Old
  • A34 and a33-Like 3dna, proteins, antibodies thereto and methods of treatment using same
    Publication number: 20060292154
    Abstract: Polynucleotide molecules and polypeptide molecules A34 and A33-like 3 are described, as well as antibodies to polypeptide molecules A34 and A33like 3. Also described are methods of detecting cancers expressing these polypeptides, and methods and kits for diagnosing said cancers, and methods of inhibiting effects of a cancer in a patient.
    Type: Application
    Filed: October 23, 2003
    Publication date: December 28, 2006
    Applicant: Ludwig Institute for Cancer Research
    Inventors: Matthew Scanlan, Cynthia Scanlan, Gerd Ritter, Lloyd Old, Achim Jungbluth
  • Isolated peptides corresponding to amino acid requirements of NY-ESO-1, which bind to MHC Class I and MHC Class II molecules, and uses thereof
    Publication number: 20060269960
    Abstract: The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.
    Type: Application
    Filed: August 4, 2006
    Publication date: November 30, 2006
    Inventors: Alexander Knuth, Elke Jager, Yao-tseng Chen, Matthew Scanlan, Ali Gure, Gerd Ritter, Lloyd Old, Jan Drijfhout
  • Isolated cancer associated antigens NY-MEL 1 and NY-MEL 3, peptides based thereon, and their uses
    Patent number: 7132507
    Abstract: The invention relates to isolated, cancer associated antigens, nucleic acid molecules, and various uses thereof.
    Type: Grant
    Filed: May 21, 2002
    Date of Patent: November 7, 2006
    Assignees: Ludwig Institute for Cancer Research, Memorial Sloan-Kettering Cancer Center, Cornell Research Foundation, Inc.
    Inventors: Dirk Jager, Elizabeth Stockert, Matthew Scanlan, Ali Gure, Elke Jager, Alexander Knuth, Lloyd Old, Yao-Tseng Chen
  • Isolated nucleic acid molecules which encode peptides which bind to MHC class II molecules, such as HLA-DR53
    Patent number: 7115729
    Abstract: The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts.
    Type: Grant
    Filed: January 2, 2004
    Date of Patent: October 3, 2006
    Assignees: Cornell Research Foundation, Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center
    Inventors: Alexander Knuth, Elke Jäger, Yao-tseng Chen, Matthew Scanlan, Ali Gure, Gerd Ritter, Lloyd J. Old, Jan W. Drijfhout